MERZ THERAPEUTICS TO PRESENT ROBUST DATA ON XEOMIN® (INCOBOTULINUMTOXINA) AT TOXINS 2022 CONFERENCE
- 10 accepted abstract presentations provide important updates and data on XEOMIN
- Abstracts also published in Toxicon, a peer-reviewed interdisciplinary journal on toxins
Merz Therapeutics announced today the presentation of data from 10 accepted abstracts on XEOMIN® (incobotulinumtoxinA) at TOXINS 2022: Basic Science and Clinical Aspects of Botulinum and Other Neurotoxins, taking place in New Orleans, LA July 27-30.
“Merz Therapeutics is excited to present strong data at the global TOXINS 2022 conference, and share important updates and clinical developments for XEOMIN, including data on clinical benefits to children and adolescents living with movement disorders in the United States,” said Prof. Dr. Florian Heinen, Head of Pediatric Neurology at LMU University Hospital Munich.* “The data assessing the ability of XEOMIN to help improve pain in children living with movement disorders is an important finding, and I am proud to be involved in this research.”
The following presentations will be shared at the TOXINS meeting and are intended to enhance the exchange of scientific information. All associated abstracts will be published in an online supplemental issue of Toxicon.
ORAL & VIDEO ABSTRACT PRESENTATION
- Prevalence of spasticity-related pain in a clinical study population of children/adolescents with cerebral palsy, Florian Heinen, Michaela Bonfert, Petr Kaňovský, A. Sebastian Schroeder, Henry G. Chambers, Edward Dabrowski, Thorin L. Geister, Angelika Hanschmann, Michael Althaus, Marta Banach, Deborah Gaebler-Spira
SCIENTIFIC E-POSTER PRESENTATIONS
- Injections of IncobotulinumtoxinA at Intervals Less Than 10 weeks Are Effective and Safe for Cervical Dystonia Patients With Inadequate Benefit From Standard Injection Intervals, Cynthia Comella, Robert Hauser, Stuart Isaacson, Georg Comes, Michael Hast, David Charles
- Treatment of Cervical Dystonia Using Shorter IncobotulinumtoxinA Injection Intervals Improves Patient-Reported Outcomes in Those With Inadequate Benefits From Standard Intervals, Robert Hauser, David Charles, Cynthia Comella, Georg Comes, Michael Hast, Stuart Isaacson
- Immunogenicity of Botulinum Toxin Formulations: Potential Therapeutic Implications, Warner Carr, Neal Jain, Wesley Sublett
- Real-World Cost and Utilization Analysis of Botulinum Toxin Agents in Blepharospasm: A National Retrospective Cohort Study, Rashid Kazerooni, Daniel B. Rootman, Robert Goldberg, Liza M. Cohen
- Improvements in upper limb spasticity-related pain in children/adolescents with cerebral palsy after incobotulinumtoxinA injections, Florian Heinen, Michaela Bonfert, Petr Kaňovský, A. Sebastian Schroeder, Henry G. Chambers, Edward Dabrowski, Thorin L. Geister, Angelika Hanschmann, Michael Althaus, Marta Banach, Deborah Gaebler-Spira
- Improvements in lower limb spasticity-related pain in children/adolescents with cerebral palsy after incobotulinumtoxinA injections, Florian Heinen, Michaela Bonfert, Petr Kaňovský, A. Sebastian Schroeder, Henry G. Chambers, Edward Dabrowski, Thorin L. Geister, Angelika Hanschmann, Michael Althaus, Marta Banach, Deborah Gaebler-Spira
- Pain reduction in adult patients with limb spasticity following a single incobotulinumtoxinA injection: an analysis of pooled data from phase 2 and 3 studies, Jörg Wissel, Alexandre Camões-Barbosa, Georg Comes, Michael Althaus, Astrid Scheschonka, David Simpson
- Benefit of multiple incobotulinumtoxinA injections for pain reduction in adult patients with limb spasticity: an analysis of pooled data from phase 2 and 3 studies, Jörg Wissel, Alexandre Camões-Barbosa, Georg Comes, Michael Althaus, Astrid Scheschonka, David Simpson
- Disparities in Access to Spasticity Chemodenervation Specialists in the United States: A National Analysis of Medicare Data, Rashid Kazerooni, Sean Healy, Monica Verduzco-Gutierrez
Presentations will be accessible in the on-site poster hall for the duration of the meeting beginning on Wednesday, July 27. Conference attendees will also have access to the virtual conference hall for six months post-conference.
*Prof. Dr. Florian Heinen is a paid consultant for Merz Pharmaceuticals GmbH.
|XEOMIN® (incobotulinumtoxinA) IMPORTANT CONSUMER SAFETY INFORMATION
Read the Medication Guide before you start receiving XEOMIN® (Zeo-min) and each time XEOMIN is given to you as there may be new information. The risk information provided here is not comprehensive. To learn more:
· Talk to your health care provider or pharmacist
· Visit www.xeomin.com to obtain the FDA-approved product labeling
· Call 1-844-4MYMERZ (1-844-469-6379)
XEOMIN is a prescription medicine:
It is not known if XEOMIN is safe and effective in children younger than:
XEOMIN may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of XEOMIN:
These symptoms can happen hours to weeks after you receive an injection of XEOMIN. These problems could make it unsafe for you to drive a car or do other dangerous activities.
Do not take XEOMIN if you: are allergic to XEOMIN or any of the ingredients in XEOMIN (see below for a list of ingredients in XEOMIN), had an allergic reaction to any other botulinum toxin product such as rimabotulinumtoxinB (Myobloc®), onabotulinumtoxinA (Botox®, Botox® Cosmetic), or abobotulinumtoxinA (Dysport®) or have a skin infection at the planned injection site.
Before receiving XEOMIN, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Talk to your doctor before you take any new medicines after you receive XEOMIN.
Especially tell your doctor if you:
Ask your doctor if you are not sure if your medicine is one that is listed above.
Know the medicines you take. Keep a list of your medicines with you to show your doctor and pharmacist each time you get a new medicine.
Possible Side Effects
XEOMIN can cause serious side effects including:
The most common side effects of XEOMIN in adults with chronic sialorrhea include:
The most common side effects of XEOMIN in children 2 to 17 years of age with chronic sialorrhea include:
The most common side effects of XEOMIN in adults with upper limb spasticity include:
The most common side effects of XEOMIN in children 2 to 17 years of age with upper limb spasticity include:
The most common side effects of XEOMIN in adults with cervical dystonia include:
The most common side effects of XEOMIN in adults with blepharospasm include:
These are not all the possible side effects of XEOMIN.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
|General information about the safe and effective use of XEOMIN
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. You can ask your pharmacist or doctor for information about XEOMIN that is written for health professionals.
|Active Ingredient: botulinum toxin type A
Inactive Ingredients: human albumin and sucrose
Copyright © 2022 Merz Pharmaceuticals, LLC. All rights reserved. MERZ, the MERZ logo, and
XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA. Botox, Dysport and
Myobloc are registered trademarks of their respective owners.